DV
Dividend Vision

FBRX — Forte Biosciences Inc

Forte Biosciences Inc (FBRX)

Total return is -98.4% over the past 9.3 years, 384.5 points behind SPY at 286.1%. Its deepest 1-year drawdown was 55.9%.

Forte Biosciences is a clinical-stage biopharmaceutical company developing FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related indications including celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company does not currently distribute dividends. Forte Biosciences appeals primarily to investors seeking exposure to early-stage biopharmaceutical development rather than current income.

FBRX key facts

Asset type
Stock
Asset class
Equity
Inception date
04/13/2017
Last close
$76.83
Market cap
$1,000,594,944
Average volume
490200.0
Payment date
06/16/2020
Beta
2.844
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.58